Payment overview · 2025
General Payments
$905.34
51 reported records · 9 companies
Healthcare provider profile · identity verified
Logan Dameron
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · KNOXVILLE, TN · NPI 1083260764
Verified facts
What the public records show
CMS Open Payments records show Logan Dameron received $905.34 in general payments during 2025 across 51 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $318.46 | 35.2% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $164.45 | 18.2% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.65 | 18.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.76 | 7.5% | 4 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $64.32 | 7.1% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $48.38 | 5.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $43.01 | 4.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.47 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.84 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $905.34 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $318.46 | 20 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.48 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.76 | 4 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $64.32 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $48.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.07 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 257 | 54 |
| Gabapentin | Gabapentin | 183 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 39 |
| Lisinopril | Lisinopril | 126 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 44 |
| Furosemide | Furosemide | 103 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 35 |
| Simvastatin | Simvastatin | 86 | 25 |
| Famotidine | Famotidine | 85 | 27 |
| Alprazolam | Alprazolam | 83 | 27 |
| Potassium Chloride | Potassium Chloride | 82 | 21 |
| Metformin Hcl | Metformin Hcl | 77 | 29 |
| Alendronate Sodium | Alendronate Sodium | 75 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 24 |
| Trazodone Hcl | Trazodone Hcl | 75 | 26 |
| Gemfibrozil | Gemfibrozil | 71 | 13 |
| Montelukast Sodium | Montelukast Sodium | 71 | 12 |
| Buspirone Hcl | Buspirone Hcl | 69 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 19 |
| Fenofibrate | Fenofibrate | 65 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 20 |
| Prednisone | Prednisone | 61 | 37 |
| Losartan Potassium | Losartan Potassium | 58 | 23 |
| Carvedilol | Carvedilol | 56 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 18 |
| Glimepiride | Glimepiride | 53 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Azithromycin | Azithromycin | 43 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Baclofen | Baclofen | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Eliquis | Apixaban | 33 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 13 |
| Ibuprofen | Ibuprofen | 32 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Atenolol | Atenolol | 31 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 13 |
| Ozempic | Semaglutide | 31 | 11 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 11 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | 12 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | 11 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Enskyce | Desogestrel-Ethinyl Estradiol | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $905.34 · 51 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, GIMOTI, INSPIRE, Kerendia, Ozempic, REXULTI, Rybelsus, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error